

---

**Product Data Sheet**


---

Product Name: Rp-8-bromo-Cyclic GMPS (sodium salt)

Cat. No.: GC10517

**Chemical Properties**

Cas. No. 208445-06-1

Chemical Name 8-bromo-guanosine cyclic 3',5'-[(R)-(hydrogen phosphorothioate)], monosodium salt

SMILES O[C@H]1[C@H](N2C(Br)=NC3=C2N=C(N)NC3=O)O[C@H]4[C@H]1O[P@@](OC4)([S-])=O.[Na+]Formula  $C_{10}H_{10}BrN_5O_6PS \cdot Na$  M.Wt 462.1Solubility  $\leq 3.6\text{mg/ml}$  in ethanol;  $12.5\text{mg/ml}$  in DMSO;  $16.7\text{mg/ml}$  in dimethyl formamide Storage Store at  $-20^\circ\text{C}$ General tips For obtaining a higher solubility, please warm the tube at  $37^\circ\text{C}$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^\circ\text{C}$  for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure **Background**

Rp-8-bromo-Cyclic GMPS is a cGMP-dependent protein kinase (cGK) inhibitor.

cGMP is considered as an important regulator of vascular smooth muscle tone. Several smooth muscle relaxants including nitrogen oxide-containing vasodilators), endothelial-derived relaxing factors, and atrial natriuretic peptides can stimulate cGMP production in vascular smooth muscle. In addition, many of these agents have been shown to inhibit  $\text{Ca}^{2+}$ -stimulated enzymes such as phosphorylase kinase and myosin light chain kinase in aortic smooth muscle, indicating that one major role of cGMP is to reduce the levels of free intracellular  $\text{Ca}^{2+}$ .

In vitro: The effects of Rp-8-bromo-Cyclic GMPS on intracellular calcium concentrations in cultured rat aortic smooth muscle cells were studied. Results showed that both angiotensin II and depolarizing concentrations of  $\text{K}^+$  were able to stimulate  $\text{Ca}^{2+}$

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

accumulation in the cytoplasm. The increase in  $\text{Ca}^{2+}$  because of angiotensin II was associated with an increase in inositol phosphates, while that due to  $\text{K}^{+}$  was not. Preincubation of cells with Rp-8-bromo-Cyclic GMPS at 100  $\mu\text{M}$  could cause an inhibition of peak  $\text{Ca}^{2+}$  accumulation to either angiotensin II or  $\text{K}^{+}$  [1]. Another study found that like 8-bromo-cGMP, Rp-8-bromo-Cyclic GMPS was also resistant to hydrolysis by phosphodiesterases. This Rp isomer could bind cGK without activating it, leading to the competitive inhibition [2].

In vivo: Up to now, there is no animal in vivo data reported.

Clinical trial: So far, no clinical study has been conducted.

### References:

[1] Rashatwar, S. S., Cornwell, T.L. and Lincoln, T.M. Effects of 8-bromo-cGMP on  $\text{Ca}^{2+}$  levels in vascular smooth muscle cells: Possible regulation of  $\text{Ca}^{2+}$ -ATPase by cGMP-dependent protein kinase. Proceedings of the National Academy of Sciences of the United States of America 84(16), 5685-5689 (1987).

[2] Butt, E. ,Phler, D.,Genieser, H.G., et al. Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS. British Journal of Pharmacology 116, 3110-3116 (1995).

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA